Slc5a2

Summary

Gene Symbol: Slc5a2
Description: solute carrier family 5 (sodium/glucose cotransporter), member 2
Alias: Sglt2, sodium/glucose cotransporter 2, Na(+)/glucose cotransporter 2, low affinity sodium-dependent glucose cotransporter, low affinity sodium-glucose cotransporter, solute carrier family 5 member 2
Species: mouse
Products:     Slc5a2

Top Publications

  1. Vallon V, Platt K, Cunard R, Schroth J, Whaley J, Thomson S, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104-12 pubmed publisher
    Mutations in the gene encoding for the Na(+)-glucose co-transporter SGLT2 (SLC5A2) associate with familial renal glucosuria, but the role of SGLT2 in the kidney is incompletely understood...
  2. Sabolic I, Vrhovac I, Eror D, Gerasimova M, Rose M, Breljak D, et al. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302:C1174-88 pubmed publisher
    With a novel antibody against the rat Na(+)-D-glucose cotransporter SGLT2 (rSGLT2-Ab), which does not cross-react with rSGLT1 or rSGLT3, the ?75-kDa rSGLT2 protein was localized to the brush-border membrane (BBM) of the renal proximal ..
  3. Tabatabai N, Blumenthal S, Lewand D, Petering D. Differential regulation of mouse kidney sodium-dependent transporters mRNA by cadmium. Toxicol Appl Pharmacol. 2001;177:163-73 pubmed
    ..full-length cDNA clones encoding both high- and low-affinity sodium-dependent glucose transporters SGLT1 and SGLT2, respectively, from cultured mouse kidney cortical cells...
  4. Wiley L, Lever J, Pape C, Kidder G. Antibodies to a renal Na+/glucose cotransport system localize to the apical plasma membrane domain of polar mouse embryo blastomeres. Dev Biol. 1991;143:149-61 pubmed
    ..The onset of cell surface expression of this antigen precedes development of the stable polar phenotype. ..
  5. Ye Y, Bajaj M, Yang H, Perez Polo J, Birnbaum Y. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31:119-132 pubmed publisher
    We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice...
  6. Vallon V, Rose M, Gerasimova M, Satriano J, Platt K, Koepsell H, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304:F156-67 pubmed publisher
    The Na-glucose cotransporter SGLT2 mediates high-capacity glucose uptake in the early proximal tubule and SGLT2 inhibitors are developed as new antidiabetic drugs...
  7. Chiba Y, Yamada T, Tsukita S, Takahashi K, Munakata Y, Shirai Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS ONE. 2016;11:e0150756 pubmed publisher
    ..Collectively, these results suggest that SGLT2i treatment acutely suppresses energy expenditure in BAT via regulation of an inter-organ neural network consisting of the common hepatic vagal branch and sympathetic nerves. ..
  8. Jiang M, Wang Q, Karasawa T, Koo J, Li H, Steyger P. Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides. PLoS ONE. 2014;9:e108941 pubmed publisher
    ..resides within kidney proximal tubules that also heavily express electrogenic sodium-glucose transporter-2 (SGLT2; SLC5A2) in vivo. We hypothesized that SGLT2 traffics gentamicin, and promotes cellular toxicity...
  9. Kosfeld A, Brand F, Weiss A, Kreuzer M, Goerk M, Martens H, et al. Mutations in the leukemia inhibitory factor receptor (LIFR) gene and Lifr deficiency cause urinary tract malformations. Hum Mol Genet. 2017;26:1716-1731 pubmed publisher
    ..3% of CAKUT patients, and provide evidence that Lifr deficiency and deactivating LIFR mutations cause highly similar anomalies of the urogenital tract in mice and humans. ..

More Information

Publications22

  1. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov V, Hohenstein B, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307:F317-25 pubmed publisher
    ..The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion...
  2. Atageldiyeva K, Fujita Y, Yanagimachi T, Mizumoto K, Takeda Y, Honjo J, et al. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice. PLoS ONE. 2016;11:e0157672 pubmed publisher
    A low carbohydrate diet (LCHD) as well as sodium glucose cotransporter 2 inhibitors (SGLT2i) may reduce glucose utilization and improve metabolic disorders...
  3. Zhao Y, Gao P, Sun F, Li Q, Chen J, Yu H, et al. Sodium Intake Regulates Glucose Homeostasis through the PPAR?/Adiponectin-Mediated SGLT2 Pathway. Cell Metab. 2016;23:699-711 pubmed publisher
    ..PPAR? activation in perirenal fat by agonist or high sodium intake inhibited renal sodium-glucose cotransporter 2 (SGLT2) function, which is mediated by increased production of adipose adiponectin...
  4. Okauchi S, Shimoda M, Obata A, Kimura T, Hirukawa H, Kohara K, et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun. 2016;470:772-782 pubmed publisher
    It is well known that Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors, new hypoglycemic agents, improve glycemic control by increasing urine glucose excretion, but it remained unclear how they exert protective effects on pancreatic Î..
  5. Bonner C, Kerr Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-7 pubmed publisher
    ..We further found that expression of SLC5A2 (which encodes SGLT2) was lower and glucagon (GCG) gene expression was higher in islets from T2D individuals and ..
  6. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell D, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188-93 pubmed publisher
    In the kidney, the sodium-glucose cotransporters SGLT2 and SGLT1 are thought to account for >90 and ?3% of fractional glucose reabsorption (FGR), respectively...
  7. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. Diab Vasc Dis Res. 2016;13:438-441 pubmed
    ..Inhibition of glucose entry into tubular cells by tofogliflozin may exert renoprotective properties in diabetes. ..
  8. Pontoglio M, Prie D, Cheret C, Doyen A, Leroy C, Froguel P, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1:359-65 pubmed
    ..The renal murine defect is due to reduced expression of the low affinity/high capacity glucose cotransporter (SGLT2). Our results show that HNF1alpha directly controls SGLT2 gene expression...
  9. Sawada Y, Izumida Y, Takeuchi Y, Aita Y, Wada N, Li E, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. Biochem Biophys Res Commun. 2017;493:40-45 pubmed publisher
    Sodium-glucose cotransporter 2 (SGLT2) inhibitors have both anti-diabetic and anti-obesity effects. However, the precise mechanism of the anti-obesity effect remains unclear...
  10. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. Arch Pharm Res. 2016;39:259-270 pubmed publisher
    The sodium-glucose cotransporter 2 (SGLT2) is responsible for most glucose reabsorption in the kidney and has been proposed as a novel therapeutic target for the treatment of type 2 diabetes...
  11. Unno K, Yamamoto H, Toda M, Hagiwara S, Iguchi K, Hoshino M, et al. Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10. Biochem Biophys Res Commun. 2014;454:89-94 pubmed publisher
    ..In the present study, we characterized SAMP10/TaSlc mice and further identified a spontaneous mutation in the Slc5a2 gene encoding sodium-glucose co-transporter (SGLT) 2...
  12. Powell D, Dacosta C, Gay J, Ding Z, Smith M, Greer J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304:E117-30 pubmed publisher
    Sodium-glucose cotransporter 2 (SGLT2) is the major, and SGLT1 the minor, transporter responsible for renal glucose reabsorption...
  13. Jurczak M, Lee H, Birkenfeld A, Jornayvaz F, Frederick D, Pongratz R, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890-8 pubmed publisher
    Inhibition of the Na(+)-glucose cotransporter type 2 (SGLT2) is currently being pursued as an insulin-independent treatment for diabetes; however, the behavioral and metabolic consequences of SGLT2 deletion are unknown...